Market Reports on China Provides the Trending Market Research Report on “China Recombinant Human Endostatin Market Report 2019-2023”under Life Sciences Category. The report offers a collection of superior market research, market analysis, competitive intelligence and Market reports.

Recombinant Human Endostatin, an angiogenesis inhibitor, was developed by a Chinese enterprise in 1999 and approved by the China Food and Drug Administration (CFDA) in 2005 to be used in the combination chemotherapy for the recurrence and metastasis of NSCLC. Recombinant Human Endostatin acts on vascular endothelial cells to inhibit the movement of endothelial cells that form blood vessels and the formation of tumor angiogenesis and block the nutrition supply to tumor cells. In this way, it inhibits tumor proliferation or metastasis.

Request a free sample copy of Recombinant Human Endostatin Market Report @
http://www.marketreportsonchina.com/marketreports/sample/reports/1745613

Description In 2008, lung cancer replaced liver cancer to be the malignant tumor with the highest fatality rate in China. Over the past 30 years, lung cancer has become a heavy burden on the Chinese people and society.
In 2017, the number of lung cancer patients in China rose to 800,000; 700,000 people died of lung cancer, accounting for over 20% of the cancer deaths in China. The incidence of lung cancer is growing at an annual rate of more than 20%. It is expected that in 2025, lung cancer will kill nearly 1 million people in China. In 2017, the number of lung cancer patients in China and the number of people died of lung cancer in China both accounted for 40% of the global total. And about 80% of the lung cancer patients had non-small cell lung cancer (NSCLC).

In 2008, lung cancer replaced liver cancer to be the malignant tumor with the highest fatality rate in China. Over the past 30 years, lung cancer has become a heavy burden on the Chinese people and society.

In 2017, the number of lung cancer patients in China rose to 800,000; 700,000 people died of lung cancer, accounting for over 20% of the cancer deaths in China. The incidence of lung cancer is growing at an annual rate of more than 20%. It is expected that in 2025, lung cancer will kill nearly 1 million people in China. In 2017, the number of lung cancer patients in China and the number of people died of lung cancer in China both accounted for 40% of the global total. And about 80% of the lung cancer patients had non-small cell lung cancer (NSCLC).

Browse our full report with Table of Contents:
http://www.marketreportsonchina.com/marketreports/investigation-report-on-china-s-recombinant-human-endostatin-market-2019-2023/1745613

About Market Reports on China:
Market Reports on China is thus the one-stop solution for the entire market research requirements with regards to China. We provide you with insight and analysis on the country’s economic outlook at the national, regional and city level, presenting deep understanding of disparities and evolutionary paths. Get a complete, consistent and concise view of your markets with comprehensive industry reports. Our latest regional databanks, forecasts, and detailed risk ratings will help you to identify risk and opportunities in every industry and develop strategic plans to deal with the competitiveness in the Chinese market.

Contact us:
Market Reports on China
Tel: +91 22 27810772 / 27810773
Email:[email protected]
Website: http://www.marketreportsonchina.com
Follow us on: Twitter, Facebook, LinkedIn